Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort
Jacqueline N. Poston(University of Vermont), Rebecca Kruse‐Jarres(University of Washington), Craig M. Kessler(Georgetown University), Osman Khan(University of Oklahoma Health Sciences Center), Evan C. Chen(Dana-Farber Cancer Institute), Patrick Ellsworth(University of North Carolina at Chapel Hill), Maissaa Janbain(Tulane University), Kadhim Al-Banaa(University of California San Diego), Aric Parnes(Brigham and Women's Hospital), Lorraine Cafuir(Emory University), Lynn Malec(Medical College of Wisconsin), Cassandra Bryan(Washington Center), Miguel A. Escobar, Jenny Y. Zhou(University of California San Diego), James Fan Wu(Medical College of Wisconsin), Christopher A. Walsh(Broad Institute), Annette von Drygalski(University of California San Diego)
Cited by 10
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
|New England Journal of Medicine|2003|809
A Prospective Study of Human Immunodeficiency Virus Type 1 Infection and the Development of AIDS in Subjects with Hemophilia
|New England Journal of Medicine|1989|528
Disruption of neural progenitors along the ventricular and subventricular zones in periventricular heterotopia
|Human Molecular Genetics|2008|187